Evaxion biotech completes recruitment for phase 1/2a clinical trial for evx-02

Copenhagen, denmark, march 07, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, has now finalized recruitment for phase 1/2a clinical trial of evx-02 in adjuvant melanoma patients.

EVAX Ratings Summary

EVAX Quant Ranking